Product Pipelines

Focusing on unmet clinical needs, we commit to developing better drugs for better lives. We have robust product lines in therapeutic fields of anesthesia, cardiovascular diseases and eye diseases, which include 1 product in NDA stage, 3 products in clinical stage and 5 products in pre-clinical stage.

企业招聘3327(1)

企业招聘3327(1)

副标题

Adamgammadex (Aom0498)---Patented selective neuromuscular reversal agent antagonizing rocuronium
Adamgammadex (Aom0498) is a second-generation selective neuromuscular blockade reversal agent developed by Aomo. Adamgammadex is indicated for reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in patients undergoing surgery. Adamgammadex can rapidly reverse neuromuscular blockade in intraoperative or postoperative stage, eliminate the risks and side effects related to residual neuromuscular blockade, and effectively improve the safety and success rate of surgery.
















Adamgammadex has good biocompatibility and molecular-targeted binding properties, which can rapidly and stably reverse rocuronium-induced neuromuscular blockade. The effects of adamgammadex are stable after administration and recurarization is rare. Adamgammadex is of great safety and will not cause safety issues such as prolonged QT interval, bleeding or allergic reactions.

As non-clinical and clinical data show, adamgammadex can rapidly reverse different levels of rocuronium-induced neuromuscular blockade in 3 minutes, and significantly reduce the risk of respiratory depression caused by residual neuromuscular blockade and the incidence of postoperative complications.  


Pooled data of completed Phase II and Phase III studies on the efficacy of adamgammadex in reversing rocuronium-induced moderate neuromuscular blockade shows, adamgammadex is of greater safety compared with sugammadex in aspects of allergic reactions, recurarization and laryngospasm (0% vs 2.81%, P=0.024).


Two pivotal Phase III clinical trials (indicated for reversing rocuronium-induced moderate and deep neuromuscular blockade) of adamgammadex in China have been completed, and the NDA application is expected to be submitted to The National Medical Products Administration (NMPA) in 2024. Meanwhile, the End-of-Phase II (EOP2) meeting with the FDA has been held successfully, and the multi-regional clinical trials (MRCT) in the US, Japan and Europe are scheduled to initiated in 2024.

Identifier No.

Phase

Study Title

CTR20213282

Phase III

Pivotal Phase III clinical studies of adamgammadex sodium in reversing deep neuromuscular blockade

Link CDE

CTR20211477

Phase III

Pivotal Phase III clinical studies of adamgammadex sodium in reversing moderate neuromuscular blockade

Link CDE

CTR20200840

Phase IIb

Phase IIb clinical studies of adamgammadex sodium in reversing rocuronium-induced deep neuromuscular blockade

Link CDE

CTR20191479

Phase IIa

Phase IIa clinical studies of adamgammadex sodium in reversing rocuronium-induced deep neuromuscular blockade

Link CDE

CTR20181917

Phase II

Phase II clinical studies of adamgammadex sodium in reversing rocuronium-induced moderate neuromuscular blockade

Link CDE

CTR20180893

Phase I

Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Adamgammadex Sodium for Injection in Healthy Subjects

‍Link CDE

CTR20170503

Phase I

Phase I Dose escalation clinical studies of adamgammadex sodium for injection

Link CDE


Aom0499--- Patented targeting neuromuscular reversal agent antagonizing cisatracurium

Preclinical studies indicated that Aom0499 can effectively reverse cisatracurium-induced neuromuscular blockade through new target and new mechanism. Once marketed, Aom0499 will become a formidable competitor to Bridion® of Merck Sharp & Dohme in all aspects and be far ahead of other neuromuscular reversal agents around the world.


With Aom0498 and Aom0499, Aomo will cover more than 90% of market share for neuromuscular reversal agents in the world and become the only pharmaceutical company who owns reversal agents for nondepolarizing muscular relaxants and benzylisoqunoline muscular relaxants.

Aom0777---Novel sedative used for procedural sedation and anaesthesia
Preclinical data demonstrated that Aom0777, as a targeting γ-aminobutyric acid (GABA) receptor agonist, has significant advantages over propofol in aspect of safety with wider therapeutical safety windows. Aom0777 overcomes technical difficulties in rapid onset and recovery.  

Aom0777 is a new-generation ultra-short-acting sedative with new structure developed by Aomo for procedural sedation/anesthesia adopted in all types of endoscopic procedures including gastroscopy, colonoscopy, hysteroscopy, fibreoptic bronchoscopy, induction and maintenance of general anesthesia in hospitalized surgical patients, and sedation in the ICU.


Aom0777 is an innovative sedative anesthetic drug with desired efficacy and safety profiles, which is obtained by innovative design of molecular structure and precise drug screening. Aom0777 has rapid onset and rapid recovery, without accumulation risk after long time application. Compared with marketed sedative anesthetic drugs, Aom0777 is of better safety, has less impact on hemodynamics and respiratory depression, and has a wider therapeutic window.


The druggability of Aom0777 has been validated, and the pre-IND studies are expected to be completed at Q1 2024, and the IND applications both in China and the US will be initiated accordingly.

Aom0315---First-in-class drug product in cardiovascular field
Aom0315 is a first-in-class patented neuroprotective agent developed by Aomo, acts through new target and new mechanism of action. Aom0315 is administered orally for protection of nerves against neurological deficits in mild to moderate acute ischemic stroke.
Phase I clinical trial of Aom0315 has been initiated in Australia, and subjects have been enrolled. All subject enrollments including subjects in Single Ascending Dose Studies (SAD) and Multiple Ascending Dose Studies (MAD) are expected to be completed by the end of 2023.

Identifier No.

Phase

Study Title

NCT05650528

Phase I

QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects

Link ClinicalTrials


Aom0319---First-in-class drug product in cardiovascular field
Aom0319 is a patented new neuroprotective agent with new target and new mechanism developed by Aomo. As an intravenous injection, Aom0319 is indicated for improving neurological deficits and related dysfunctions in acute ischemic stroke patients.
Subject enrollment of Phase I clinical trial of Aom0319 conducted in Australia has been completed. It is estimated that all subject enrollments will be completed in 2023.

Identifier No.

Phase

Study Title

NCT05555758

Phase I

Aom0319 MAD Study in Healthy Subjects

Link ClinicalTrials



Aom0304---New Chemical Entity indicated for hypertrophic cardiomyopathy

Aom0304 is a New Chemical Entity developed by Aomo for the treatment of hypertrophic cardiomyopathy. Preclinical studies have shown that Aom0304 is effective in improving the thickness of left ventricular wall during diastolic and systolic periods, which displays therapeutic effect on cardiac hypertrophy.

Aom0187---New Chemical Entity indicated for dry eye disease

Aom0187 is a New Chemical Entity of Aomo for the treatment of dry eye disease. Preclinical data indicated that Aom0187 can not only significantly improve symptoms of dry eye on animal models, but also has good therapeutic effects. Aom0187 is currently under preclinical evaluation and is expected to enter clinical stage in 2024.